Pembrolizumab/berahyaluronidase alfa

Pembrolizumab/berahyaluronidase alfa
Combination of
PembrolizumabProgrammed death receptor-1 (PD-1) blocking antibody
Berahyaluronidase alfaVariant of hyaluronidase
Clinical data
Trade namesKeytruda Qlex
License data
Routes of
administration		Subcutaneous
ATC code
  • None
Legal status
Legal status
Identifiers
KEGG

Pembrolizumab/berahyaluronidase alfa, sold under the brand name Keytruda Qlex, is a fixed dose combination medication used for the treatment of many types of solid tumors. It contains pembrolizumab, a programmed death receptor-1 (PD-1) blocking antibody; and berahyaluronidase alfa, a variant of hyaluronidase. It is given by injection under the skin (subcutaneous).

Pembrolizumab/berahyaluronidase alfa was approved for medical use in the United States in September 2025.

This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.